Esperion Therapeutics (ESPR)
(Delayed Data from NSDQ)
$2.34 USD
0.00 (0.00%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $2.37 +0.03 (1.28%) 4:56 PM ET
2-Buy of 5 2
C Value A Growth C Momentum B VGM
Esperion Therapeutics (ESPR) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$7.64 | $16.00 | $2.50 | 226.50% |
Price Target
Based on short-term price targets offered by seven analysts, the average price target for Esperion Therapeutics comes to $7.64. The forecasts range from a low of $2.50 to a high of $16.00. The average price target represents an increase of 226.5% from the last closing price of $2.34.
Analyst Price Targets (7 )
Broker Rating
Esperion Therapeutics currently has an average brokerage recommendation (ABR) of 2.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by eight brokerage firms. The current ABR compares to an ABR of 2.00 a month ago based on eight recommendations.
Of the eight recommendations deriving the current ABR, four are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 50% and 12.5% of all recommendations. A month ago, Strong Buy made up 50%, while Buy represented 12.5%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/ESPR.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 4 | 4 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 2 | 2 | 2 | 3 | 3 |
Sell | 1 | 1 | 1 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.00 | 2.00 | 2.00 | 1.88 | 1.88 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/28/2024 | Needham & Company | Serge Belanger | Moderate Buy | Moderate Buy |
6/28/2024 | H.C. Wainwright & Co. | Joseph Pantginis | Strong Buy | Strong Buy |
5/7/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
3/25/2024 | Northland Capital Markets | Carl Byrnes | Hold | Hold |
2/2/2024 | JMP Securities | Roy Buchanan | Strong Buy | Strong Buy |
1/2/2024 | BTIG | Thomas Shrader | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.00 |
ABR (Last week) | 2.00 |
# of Recs in ABR | 8 |
Average Target Price | $7.64 |
LT Growth Rate | 46.50% |
Industry | Medical - Drugs |
Industry Rank by ABR | 100 of 252 |
Current Quarter EPS Est: | -0.14 |